Greenwich LifeSciences, Inc.
NASDAQ:GLSI · NASDAQ Capital Market
-$0.74 today
Vol 0.09M · Avg 0.14M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:GLSI · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$21.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.57, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.8K -50.7% | $3.6K +0.0% | $3.6K +0.0% | $3.6K +0.0% | $3.6K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.8K +50.7% | -$3.6K +0.0% | -$3.6K +0.0% | -$3.6K +0.0% | -$3.6K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $17.2M +11.2% | $15.5M +101.1% | $7.7M +18.9% | $6.5M +81.9% | $3.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.2M +3.4% | $2.2M +32.2% | $1.6M +4.1% | $1.6M +50.7% | $1.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $19.4M +10.3% | $17.6M +89.1% | $9.3M +16.0% | $8.0M +74.9% | $4.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.8K -50.7% | $3.6K +0.0% | $3.6K +0.0% | $3.6K +0.0% | $3.6K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$19.4M -11.2% | -$17.4M -95.9% | -$8.9M -13.6% | -$7.8M -71.3% | -$4.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$19.4M -10.3% | -$17.6M -89.1% | -$9.3M -16.0% | -$8.0M -74.9% | -$4.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $89.7K -59.8% | $223.0K -48.9% | $436.1K +102.8% | $215.0K +685.7% | $27.4K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $89.7K -59.8% | $223.0K -48.9% | $436.1K +102.8% | $215.0K +685.7% | $27.4K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$19.4M -11.2% | -$17.4M -95.8% | -$8.9M -13.6% | -$7.8M -71.2% | -$4.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$19.4M -11.2% | -$17.4M -95.8% | -$8.9M -13.6% | -$7.8M -71.2% | -$4.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -18.2% | -$1 -75.4% | -$1 -13.1% | -$1 -74.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -18.2% | -$1 -75.4% | -$1 -13.1% | -$1 -74.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $13.5M +4.0% | $13.0M +1.3% | $12.8M -0.5% | $12.9M -0.2% | $12.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $13.5M +4.0% | $13.0M +1.3% | $12.8M -0.5% | $12.9M -0.2% | $12.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$507.57M
Opus Genetics, Inc.
NASDAQ:IRD
$334.39M
Surrozen, Inc.
NASDAQ:SRZN
$170.45M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$149.65M
Agenus Inc.
NASDAQ:AGEN
$122.43M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$102.65M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$95.09M
Seer, Inc.
NASDAQ:SEER
$94.57M
Tevogen Bio Holdings Inc.
TVGN
$41.94M
Atossa Therapeutics, Inc.
ATOS
$16.88M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GLSI generate?
Greenwich LifeSciences, Inc. (GLSI) reported $0.00 of revenue in fiscal 2025.
Is GLSI profitable?
Greenwich LifeSciences, Inc. (GLSI) reported -$19,358,218.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.